Abstract：Objective To observe the efficacy and safety of Roxadustat in the treatment of renal anemia in maintenance hemodialysis (MHD). Methods From August to October 2019, 15 MHD patients with renal anemia treated by the Blood Purification Center of the First People’s Hospital of Fuyang District, Hangzhou City, Zhejiang Province were selected as the study subjects, all of them received exogenous erythropoietin (EPO) treatment. The patient stopped EPO, and the iron agent was stopped at the same time when the iron agent was applied. After one week, the oral Roxadustat treatment was started, with the dose of 100-120 mg/time, three times per week, and the course of treatment was 12 weeks. The changes of hemoglobin, blood lipid (triacylglycerol [TG], total cholesterol [TC], low-density lipoprotein (LDL), high-density lipoprotein [HDL]) and ferritin were detected before and after treatment. Adverse drug reactions during treatment were recorded. Results After treatment, the hemoglobin level and ferritin level were significantly increased and decreased compared with those before treatment, with statistically significant differences (all P ＜ 0.05). After treatment, the TC and LDL levels of the patients were significantly decreased compared with those before treatment, and the differences were statistically significant (all P ＜ 0.05); however, TG and HDL of the patients did not change significantly before and after treatment, and the differences were not statistically significant (P ＞ 0.05). Conclusion Roxadustat can effectively treat renal anemia in MHD patients, which may provide a new treatment method for clinical practice.
2020, Vol. 17 
京公网安备 11010502046598号